-4 C
New York

AstraZeneca Pays $185M to Add Oral GLP-1 Drug Candidate to Pipeline

AstraZeneca gains global rights to an oral GLP-1 agonist on track to reach Phase 2 testing in 2024. Under China-based Eccogene, the small molecule’s Phase 1 data show reductions in glucose and body weight.